State Street Corp Spectrum Pharmaceuticals Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.65 - $1.31 $40,560 - $81,744	-62,400 Reduced 9.24%	612,969 $588,000
Q1 2023 May 15, 2023	BUY	$0.38 - $1.07 $38,570 - $108,605	101,500 Added 17.69%	675,369 $506,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.52 $15,904 - $25,844	-49,700 Reduced 7.97%	573,869 $212,000
Q3 2022 Nov 15, 2022	SELL	$0.43 - $1.56 $42,226 - $153,192	-98,200 Reduced 13.61%	623,569 $268,000
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.4 $1.83 Million - $3.66 Million	-2,616,547 Reduced 78.38%	721,769 $563,000
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $884,975 - $2.23 Million	-1,404,723 Reduced 29.62%	3,338,316 $4.31 Million
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.42 $15.7 Million - $30 Million	-12,393,580 Reduced 72.32%	4,743,039 $6.02 Million
Q3 2021 Nov 15, 2021	BUY	$2.15 - $3.82 $12.8 Million - $22.7 Million	5,936,588 Added 53.01%	17,136,619 $37.4 Million
Q2 2021 Aug 16, 2021	SELL	$2.89 - $4.45 $5.57 Million - $8.57 Million	-1,926,561 Reduced 14.68%	11,200,031 $42 Million
Q1 2021 May 17, 2021	BUY	$2.9 - $4.09 $7.37 Million - $10.4 Million	2,539,908 Added 23.99%	13,126,592 $42.8 Million
Q4 2020 Feb 16, 2021	BUY	$3.38 - $5.14 $12.5 Million - $19.1 Million	3,707,862 Added 53.9%	10,586,684 $36.1 Million
Q3 2020 Nov 10, 2020	BUY	$2.99 - $4.9 $278,925 - $457,101	93,286 Added 1.37%	6,878,822 $28.1 Million
Q2 2020 Aug 14, 2020	BUY	$2.11 - $3.38 $3.23 Million - $5.18 Million	1,533,171 Added 29.19%	6,785,536 $22.9 Million
Q1 2020 May 11, 2020	BUY	$1.83 - $3.45 $9.61 Million - $18.1 Million	5,252,365 New	5,252,365 $12.2 Million

Others Institutions Holding SPPI

# of Institutions

Shares Held

115K

Call Options Held

Put Options Held

Tekla Capital Management LLC

115K
Shares

$0
0.0% of portfolio

View Full List

About SPECTRUM PHARMACEUTICALS INC

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

More about SPPI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account